Differential Effect of Low-Dose Aspirin for Primary Prevention of Atherosclerotic Events in Diabetes Management: A subanalysis of the JPAD trial by Okada, Sadanori et al.
Differential Effect of Low-Dose
Aspirin for Primary Prevention
of Atherosclerotic Events in
Diabetes Management
A subanalysis of the JPAD trial
SADANORI OKADA, MD
1
TAKESHI MORIMOTO, MD, PHD
2
HISAO OGAWA, MD, PHD
3
MASAO KANAUCHI, MD, PHD
1
MASAFUMI NAKAYAMA, MD, PHD
3
SHIRO UEMURA, MD, PHD
1
NAOFUMI DOI, MD, PHD
1
HIDEAKI JINNOUCHI, MD, PHD
4
MASAKO WAKI, MD, PHD
5
HIROFUMI SOEJIMA, MD, PHD
3
MIO SAKUMA, MD, PHD
2
YOSHIHIKO SAITO, MD, PHD
1,6
FOR THE JAPANESE PRIMARY PREVENTION OF
ATHEROSCLEROSIS WITH ASPIRIN FOR
DIABETES (JPAD) TRIAL INVESTIGATORS
OBJECTIVE—Recent reports showed that low-dose aspirin was ineffective in the primary
prevention of cardiovascular events in diabetic patients overall. We hypothesized that low-dose
aspirin would be beneﬁcial in patients receiving insulin therapy, as a high-risk group.
RESEARCH DESIGN AND METHODS—This study is a subanalysis of the Japanese
Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) trial—a randomized,
controlled, open-label trial. We randomly assigned 2,539 patients with type 2 diabetes and no
previous cardiovascular disease to the low-dose aspirin group (81 or 100 mg daily) or to the
no-aspirin group. The median follow-up period was 4.4 years. We investigated the effect of
low-dose aspirin on preventing atherosclerotic events in groups receiving different diabetes
management.
RESULTS—At baseline, 326 patients were treated with insulin, 1,750 with oral hypoglycemic
agents (OHAs), and 463 with diet alone. The insulin group had the longest history of diabetes,
the worst glycemic control, and the highest prevalence of diabetic microangiopathies. The diet-
alone group had the opposite characteristics. The incidence of atherosclerotic events was 26.6,
14.6, and 10.4 cases per 1,000 person-years in the insulin, OHA, and diet-alone groups, re-
spectively. In the insulin and OHA groups, low-dose aspirin did not affect atherosclerotic events
(insulin: hazard ratio [HR] 1.19 [95% CI 0.6022.40]; OHA: HR 0.84 [0.5721.24]). In the diet-
alone group, low-dose aspirin signiﬁcantly reduced atherosclerotic events, despite the lowest
event rates (HR 0.21 [0.0520.64]).
CONCLUSIONS—Low-dose aspirin reduced atherosclerotic events predominantly in the
diet-alone group and not in the insulin or OHA groups.
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C
ardiovascular disease is one of the
major prognostic factors in patients
with diabetes (1,2). Accumulated
evidencehasshownthatlow-doseaspirin
is effective in the secondary prevention of
cardiovascular events (3). Previous stud-
ieshavesuggestedthatlow-doseaspirinis
beneﬁcial for primary prevention in
members of the general population who
areathighrisk(4–8);however,itsefﬁcacy
for patientswithdiabetes remainscontro-
versial (9).
Recently,twolargeclinicaltrials—the
Japanese Primary Prevention of Athero-
sclerosis With Aspirin for Diabetes
(JPAD) trial (10) and the Prevention of
ProgressionofArterialDiseaseandDiabe-
tes (POPADAD) trial (11)—investigated
whetherlow-doseaspirinreducedcardio-
vascular events in patients with diabetes
but without cardiovascular disease. The
JPAD trial, which was conducted by our
research group, examined the efﬁcacy of
low-dose aspirin for primary prevention
of atherosclerotic events in 2,539 Japa-
nese patients with type 2 diabetes. The
trial demonstrated that low-dose aspirin
reduced atherosclerotic events by 20%,
but statistical signiﬁcance was not
reached (10). The overall event rate was
17 cases per 1,000 person-years, which
was one-third of the expected event rate
at the start of the trial (10). Thus there
might have been too few events to pre-
cisely estimate the effect of aspirin. The
POPADAD trial, which registered 1,276
patients with either type 1 or type 2 di-
abetes in Scotland, also failed to docu-
ment an effect of aspirin (11). It was
determined that the POPADAD trial was
inconclusive because of insufﬁcient car-
diovascular events and low compliance
with aspirin therapy.
Recently, the American Diabetes Asso-
ciation (ADA), the American Heart Associ-
ation (AHA), and the American College of
Cardiology Foundation (ACCF) jointly
recommended the use of low-dose aspirin
for primary prevention of cardiovascular
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ORIGINAL ARTICLEevents only in high-risk diabetic patients
(12). Previous epidemiological studies
have reported that diabetic patients un-
dergoing insulin therapy have increased
mortality compared with those receiving
therapy with oral hypoglycemic agents
(OHAs) or diet alone (13,14). Therefore,
patients treated with insulin, deﬁned to
be a high-risk group, are considered to
be the most likely to beneﬁtf r o ml o w -
dose aspirin therapy.
In this subanalysis of the JPAD trial,
we hypothesized that low-dose aspirin
would be most beneﬁcial for primary
prevention in diabetic patients receiving
insulin therapy. We investigated the ef-
fect of low-dose aspirin on preventing
atherosclerotic events in groups catego-
rized according to type of diabetes man-
agement at baseline.
RESEARCH DESIGN AND
METHODS
Study design
T h eJ P A Dt r i a lw a sam u l t i c e n t e r ,p r o -
spective,randomized,open-label,blinded,
end point trial conducted at 163 institu-
tions throughout Japan. This trial was
performed according to the Declaration
of Helsinki and approved by the institu-
tional review board at each participating
hospital. Written informed consent was
obtainedfromeachparticipantbeforethe
trial.
The detailed design of the JPAD trial
has been previously described (10). In
brief,weenrolled2,539patients,agedbe-
tween 30 and 85 years, with type 2 diabe-
tes and no history of cardiovascular
disease. The participants were randomly
assigned to the aspirin group or the no-
aspirin group. The 1,262 patients in the
aspiringroupwereassignedtotake81mg
or 100 mg of aspirin once daily. The
1,277 patients in the no-aspirin group
were allowed to use antiplatelet therapy,
including aspirin, if needed. All patients
were allowed to use any concurrent treat-
ments.
In this subanalysis, we classiﬁed all
participants into three subgroups ac-
cording to the diabetes management at
baseline: insulin, OHA, or diet alone.
Patients with insulin and OHA combina-
tion therapy were included in the insulin
group. The diet-alone group consisted of
patients who used neither insulin nor
OHAs. The median follow-up period was
4.4 years. A total of 193 patients were lost
to follow-up, and data for those patients
were censored at the day of last follow-up.
The Consolidated Standards of Report-
ing Trials (CONSORT) diagram for the
JPAD trial was presented previously
(10).
Deﬁnition of atherosclerotic events
The primary end point was the occur-
rence during the follow-up period of any
atherosclerotic event, which was a com-
posite of the following: death from coro-
nary, cerebrovascular, and aortic causes;
nonfatal acute myocardial infarction;
unstable angina; newly developed exer-
tional angina; nonfatal ischemic and
hemorrhagic stroke; transient ischemic
attack;and nonfatalaorticandperipheral
vascular disease. All potential end points
and hemorrhagic events (gastrointestinal
bleeding and hemorrhagic stroke) were
adjudicated by an independent commit-
tee that was blinded to the group assign-
ments.
Presentation of hemoglobin A1c level
Hemoglobin A1c (HbA1c) values were
converted from the Japanese Diabetes So-
ciety (JDS) values used in the main anal-
ysis of the JPAD trial (10) into National
Glycohemoglobin Standardization Pro-
gram (NGSP) equivalent values. NGSP
equivalent values were calculated using
the following formula: NGSP equivalent
value (%) = JDS value (%) + 0.4 (15).
Statistical analyses
Categorical variables were expressed as
numberandpercentageandwerecompared
with the x
2 test. Continuous variables were
expressedasmeanvalues6SDsunlessoth-
erwise indicated. Based on their distribu-
tion, continuous variables were compared
using the Student t test or Wilcoxon rank
sum test for two-group comparisons and
ANOVA or Kruskal-Wallis test for three-
group comparisons. Cumulative inci-
dence was estimated by the Kaplan-Meier
method, and differences were assessed
with the log-rank test.
Efﬁcacycomparisonswereperformed
on the basis of time to the ﬁrst event
according to the intention-to-treat prin-
ciple, with all patients included in the
group to which they were randomized
and with patients lost to follow-up cen-
sored at the day of the last visit. Cumu-
lative incidences of end points were
estimated by the Kaplan-Meier method,
and differences between groups were
assessed with the log-rank test. We used
the Cox proportional hazard model to
estimate the hazard ratio (HR) of aspirin
use along with the 95% CI. We also
developed multivariable Cox propor-
tional hazard models to assess the effects
of aspirin on atherosclerotic events ad-
justingforage($65years),hypertension,
dyslipidemia, and history of smoking to
evaluate the robustness.
Statistical analyses were conducted
by an independent statistician (T.M.)
with the use of JMP 8.0 (SAS Institute,
Cary, NC) software and SAS 9.2 (SAS
Institute). P values of less than 0.05 were
considered statistically signiﬁcant.
RESULTS
Baseline clinical characteristics
At baseline, 326 patients were treated
with insulin, 1,750 with OHAs, and 463
with diet alone (Table 1). The mean age
wasslightlylowerintheinsulingroup(62
years) than the other groups (65 years).
MeanBMIwaslowestintheinsulingroup
(23 kg/m
2) and highest in the diet-alone
group (25 kg/m
2). Median duration of di-
abetes was longest in the insulin group:
1 3 . 0y e a r si nt h ei n s u l i ng r o u p ,7 . 2y e a r s
in the OHA group, and 3.5 years in the
diet-alone group. Mean levels of HbA1c
and fasting plasma glucose (FPG) were
8.1% and 8.77 mmol/L in the insulin
group, 7.6% and 8.27 mmol/L in the
OHA group, and 6.7% and 7.22 mmol/L
inthediet-alonegroup.Theprevalenceof
diabeticmicroangiopathieswashighestin
the insulin group (retinopathy, 43%; ne-
phropathy, 20%; neuropathy, 32%) and
lowest in the diet-alone group (retinopa-
thy, 4%; nephropathy, 8%; neuropathy,
4%).
The frequency of other cardiovascu-
lar risk factors was also investigated at
baseline (Table 1). The prevalence of hy-
pertension and dyslipidemia was signiﬁ-
cantly higher in the diet-alone group
(hypertension, 72%; dyslipidemia, 56%)
than in the other two groups. The use of
statins was low in all groups: 18, 27, and
24% in the insulin, OHA, and diet-alone
groups, respectively.Smoking historyand
family history of cardiovascular diseases
were similar among groups.
Atherosclerotic events in each
diabetes management
The incidence of atherosclerotic events
was 26.6, 14.6, and 10.4 cases per 1,000
person-years in the insulin, OHA, and diet-
alone groups, respectively (Supplementary
Table 1).Both coronary artery and cerebro-
vascular events occurred most frequently
intheinsulingroup(coronaryarteryevents,
12.1;cerebrovascular events,12.1casesper
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dence of peripheral vascular events among
the three groups (insulin, 2.4; OHA, 1.7;
diet alone, 1.6 cases per 1,000 person-
years). Survival analysis showed that the
rate of atherosclerotic events was signiﬁ-
cantly higher in the insulin group than
those in the other groups (log-rank test,
P = 0.0013; Fig. 1).
Efﬁcacy of low-dose aspirin in each
diabetes management
Participants were randomly assigned to
the aspirin group or the no-aspirin group
(Supplementary Table 2). In the insulin
group, low-dose aspirin did not affect
the incidence of atherosclerotic events
(HR 1.19 [95% CI 0.6022.40]; log-rank
test, P = 0.61; Fig. 2A). Similar results
were observed in the OHA group (HR
0.84 [0.5721.24]; log-rank test, P =
0.38; Fig. 2B). On the other hand, in
the diet-alone group, low-dose aspirin
signiﬁcantly reduced atherosclerotic
events despite the fact that this group
had the lowest atherosclerotic event rate
(HR 0.21 [0.0520.64]; log-rank test,
P = 0.0069; Fig. 2C). Adjusting for age,
hypertension, dyslipidemia, and history
ofsmoking,low-doseaspirinsigniﬁcantly
reducedatheroscleroticeventsinthediet-
alonegroup(HR0.20[0.0620.68];log-rank
test, P = 0.0099) but not in the insulin or
OHA groups (insulin: HR 1.0 [0.5022.00],
log-rank test, P =1 . 0 ;O H A :H R0 . 7 7
[0.5221.14], log-rank test, P = 0.20).
Hemorrhagic events
The number of gastrointestinal bleeding
and hemorrhagic strokes was very low
overall and seemed similar between the
aspirin and no-aspirin groups in each
diabetes management. The number of
gastrointestinal bleeding was one in the
insulin group (this patient took aspirin)
and seven in the OHA group (four in the
aspirin group and three in the no-aspirin
group). In the diet-alone group, no pa-
tients suffered from gastrointestinal
bleeding. The number of hemorrhagic
stroke was two in the insulin group (one
in the aspirin group and one in the no-
aspirin group), nine in the OHA group
(ﬁve in the aspirin group and four in the
no-aspirin group), and two in the diet-
alone group (all in the no-aspirin group).
CONCLUSIONS—Themajorﬁndings
of this subanalysis were as follows:
Japanese patients with type 2 diabetes
receiving insulin therapy had a high in-
cidence of atherosclerotic events and low-
doseaspirin reducedatheroscleroticevents
notinpatientsreceivinginsulintherapybut
in patients treated with diet alone. These
results were unchanged after adjusting for
other cardiovascular risk factors.
The patients’ baseline characteristics
categorized by diabetes management ob-
viouslydemonstratedthedifferenceindi-
abetes status (Table 1). The insulin group
was characterized by the youngest mean
age(62 years) and thelongest median du-
ration of diabetes (13.0 years), which
meant that patients in the insulin group
developed diabetes at the youngest age
among the three groups. In contrast, pa-
tients in the diet-alone group developed
diabetes in recent years and at older age.
The slightly but signiﬁcantly low BMI in
the insulin group (mean BMI, 23 kg/m
2)
Table 1—Baseline characteristics by diabetes management
Diabetes management Insulin OHA Diet alone P value
n 326 1,750 463
Age (years) 62 (10) 65 (10) 65 (10) ,0.0001
Male, n (%) 184 (56) 952 (54) 251 (54) 0.8
BMI (kg/m
2)2 3 ( 4 ) 2 4 ( 4 ) 2 5 ( 4 ) ,0.0001
Duration of diabetes (years) 13.0 (7.7–19.1) 7.2 (3.3–12.1) 3.5 (1.0–7.6) ,0.0001
HbA1c (%) 8.1 (1.5) 7.6 (1.3) 6.7 (0.8) ,0.0001
FPG (mmol/L) 8.77 (3.16) 8.27 (2.78) 7.22 (1.78) ,0.0001
Serum creatinine (mmol/L) 71 (27) 71 (27) 71 (18) 0.8
Proteinuria, n (%) 58 (18) 240 (14) 48 (10) 0.01
Diabetic retinopathy, n (%) 140 (43) 205 (12) 20 (4) ,0.0001
Diabetic nephropathy, n (%) 66 (20) 220 (13) 36 (8) ,0.0001
Diabetic neuropathy, n (%) 104 (32) 176 (10) 20 (4) ,0.0001
Diabetes medications, n (%)
Sulfonylurea 27 (8) 1,420 (81) 0 (0) ,0.0001
a-Glycosidase inhibitor 88 (27) 748 (43) 0 (0) ,0.0001
Biguanide 37 (11) 317 (18) 0 (0) ,0.0001
Thiazolidinedione 9 (3) 119 (7) 0 (0) ,0.0001
Insulin 326 (100) 0 (0) 0 (0) –
Family history of diabetes, n (%) 153 (47) 731 (42) 155 (33) 0.0003
Complications of other cardiovascular risk factors, n (%)
Hypertension 156 (48) 983 (56) 334 (72) ,0.0001
Dyslipidemia 132 (40) 953 (54) 260 (56) ,0.0001
History of smoking 146 (45) 731 (42) 182 (39) 0.3
Family history of cardiovascular diseases, n (%)
Coronary artery disease 38 (12) 198 (11) 54 (12) 0.96
Stroke 71 (22) 360 (21) 95 (21) 0.9
Dataaremean(SD)orn(%);durationofdiabetesdataaremedian(interquartilerange).BMIwascalculatedasweightinkilogramsdividedbyheightinmeterssquared.
Hypertension was deﬁned as systolic blood pressure $140 mmHg, diastolic blood pressure $90 mmHg, or therapy with antihypertensive agents. Dyslipidemia was
deﬁned as total cholesterol level $5.7 mmol/L, fasting triglyceride level $1.7 mmol/L, or therapy with antilipidemic agents.
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Okada and Associatesm i g h tb ear e ﬂection of insufﬁcient insu-
lin secretion. The glycemic control was
worst in the insulin group (mean levels
of HbA1c and FPG, 8.1% and 8.77
mmol/L) and best in the diet-alone group
(meanlevelsofHbA1candFPG,6.7%and
7.22 mmol/L). The prevalence of diabetic
microangiopathies was highest in the in-
sulin group ($20%) and lowest in the
diet alone group (,10%). There are no
deﬁnitive criteria deﬁning clinical stages
of diabetes; however, it is usually classi-
ﬁed according to the extent of vascular
complications or the level of glycemic
control. Thus we could regard the insulin
groupasdemonstratinganadvancedclin-
ical stage of diabetes and the diet-alone
group as demonstrating a less advanced
orearlierclinicalstageofdiabetesthanthe
insulinandOHAgroups.Ourresultsmight
indicate that low-dose aspirin was most
beneﬁcialinearlyclinicalstagesofdiabetes,
despite the lowest event rates.
Recently, we reported that a subanal-
ysis of the JPAD trial showed a difference
in low-dose aspirin effect on primary
prevention of atherosclerotic events in
renal function (16). In the study, reduced
renalfunctionindiabeticpatientswassig-
niﬁcantly associated with high incidence
of atherosclerotic events. Low-dose aspi-
rin did not prevent atherosclerotic events
in patients with an estimated glomerular
ﬁltrationrate(eGFR),60mL/min/1.73m
2
(HR1.3[95%CI0.7622.4]).Ontheother
hand, in the patients with an eGFR of 60
to 89 mL/min/1.73 m
2, low-dose aspirin
signiﬁcantly reduced atherosclerotic
events, despite low event rates (HR 0.57
[0.3620.88])(16).Asinthecurrentstudy,
low-dose aspirin was not beneﬁcial in pa-
tients with advanced stages of renal dys-
f u n c t i o na n dw i t hh i g he v e n tr a t e sb u t
rather in those with early stages of renal
dysfunction and with low event rates.
These results suggest that progression of
diabetesanddiabetescomplications(renal
dysfunction) might attenuate the effect of
low-dose aspirin.
The current recommendation of the
ADA, AHA, and ACCF regarding the
preventative use of aspirin in high-risk
diabetic patients is based on the number
of cardiovascular events prevented by
low-dose aspirin (relative risk reduction
of ;10%) being greater than the number
of hemorrhagic events (125 cases per
1,000 person-years) (12). Therefore,
low-dose aspirin use depends on individ-
ual cardiovascular risk. Because diabetic
patients with higher cardiovascular
risk should have greater absolute beneﬁt
from low-dose aspirin, our ﬁndings were
unexpected and inconsistent with the rec-
ommendation. To conﬁrm whether low-
dose aspirin is really effective in high-risk
or low-risk diabetic patients, further in-
vestigations are needed.
One possible mechanism of our ﬁnd-
ings is that events in patients with advanced
clinicalstagesofdiabetesareunpreventable
because of overly advanced atherosclerotic
lesions. Another possible mechanism is
aspirin resistance in diabetic patients with
poor glycemic control. Aspirin resistance
is often described as a phenomenon
whereby patients develop cardiovascular
disease despite aspirin intake. The details
surrounding aspirin resistance remain
obscure, but it is thought to be affected
by underlying interindividual variability
(17). Increased platelet aggregation has
been observed in patients with diabetes
(18). Several studies have reported that
aspirin’s antiplatelet function is lower in
diabetic patients than in nondiabetic pa-
tients (19) and that the frequency of as-
pirin resistance is positively correlated
with the levels of HbA1c and FPG (20).
Higher aspirin doses have been shown to
improve aspirin resistance in patients
with diabetes (19). In our study, poor gly-
cemic control in the insulin group might
diminish the effects of aspirin via com-
monly occurring aspirin resistance. In-
creasing aspirin dosage may improve
antiplatelet function, but there are insufﬁ-
cientdataregardingtheeffectofhigh-dose
aspirin on the prevention of cardiovascu-
lar events at this time (12). Combination
therapywithaspirinandotherantiplatelet
agents, such as clopidogrel, suppresses
platelet aggregation more strongly (19),
but the beneﬁt of dual antiplatelet ther-
apy on primary prevention is also incon-
clusive (21).
The differing prevalence of other car-
diovascular risk factors among patients
in the various diabetic treatment groups
might alter the low-dose aspirin effect on
primary prevention of atherosclerotic
events. In the diet-alone group, a high
prevalence of hypertension (72%) and
dyslipidemia (56%), high age (mean age,
65years),mildoverweight(meanBMI,25
kg/m
2), and mild glucose intolerance
(mean levels of HbA1c and FPG, 6.7%
and 7.22 mmol/L) might indicate that
these patients could be considered to
have multiple cardiovascular risk factors
rather than overt diabetes. In fact, previ-
ous clinical trials of primary prevention
in patients with multiple cardiovascular
risk factors showed that low-dose aspi-
rin reduced cardiovascular events (5–7),
whereas no trial provided a deﬁnitive
conclusion regarding patients with diabe-
tes (9–11). The Primary Prevention Pro-
ject (PPP) trial reported a difference in
the effect of low-dose aspirin on primary
prevention between patients with and
without overt diabetes (22). The PPP
trial enrolled 4,495 patients with at least
one major cardiovascular risk factor,
Figure 1—Incidence of atherosclerotic events in each diabetes management. Survival analysis
showed that the rate of atherosclerotic events was signiﬁcantly higher in the insulin group (log-
rank test, P = 0.0013).
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betes (FPG $7.8 mmol/L or treated with
OHAs). This trial showed that low-dose
aspirin lowered the incidence of cardio-
vascular events by 33% in total (7); how-
ever, in the diabetic group, low-dose
aspirin did not reduce cardiovascular
events despite 50% higher event rates
(22). These reports might conﬁrm that
low-dose aspirin was beneﬁcial in the
diet-alone group, as a subset of patients
in the early clinical stages of diabetes and
with comorbid other cardiovascular risk
factors.
Recent meta-analyses, including data
from the JPAD trial, reported that low-
doseaspirinisnot effectivein theprimary
prevention of cardiovascular events in
patients with diabetes (9,23). Patients
treated with insulin are at high risk for
cardiovascular events; however, our ﬁnd-
ings indicated that low-dose aspirin re-
duced atherosclerotic events not in the
insulingroupbutinthediet-alonegroup.
These results suggest that low-dose aspi-
rintherapyismostbeneﬁcialinearlyclin-
ical stages of diabetes. When clinicians
use low-dose aspirin in diabetic patients
to prevent cardiovascular events, they
should take into account not only con-
ventional cardiovascular risk factors but
also the clinical stage of diabetes. Further
studies are needed to assess the effect of
low-dose aspirin at each clinical stage of
diabetes.
Study strengths and limitations
Our project is the ﬁrst report to estimate
the effect of low-dose aspirin on the
primary prevention of atherosclerotic
events in groups undergoing various di-
abetes management strategies. Our results
suggestthattheclinicalimpactoflow-dose
aspirin depends on the clinical stage of
diabetes. However, this subanalysis has
several limitations in addition to those
reported in the main JPAD report (10).
First, we used the management of di-
abetesatbaselineasasubgroupingvariable.
As with other variables, the management
modality could change over time. Such
changes could be especially frequent in
t h ed i e t - a l o n ea n dO H Ag r o u p sa st h e y
begin to require more intensive treatment,
and as a result the subgrouping might
not be valid. Second, the small number of
patients in each treatment group, espe-
cially in the insulin group, limited the
certainty with which we could formulate
conclusions regarding aspirin’s effect.
Larger studies are needed for deﬁnitive
evaluation of the effect of aspirin in
Figure 2—Efﬁcacy of low-dose aspirin on primary prevention of atherosclerotic events in each
diabetes management. A and B: In the insulin (A)a n dO H A( B) groups, low-dose aspirin did not
affecttheincidenceofatheroscleroticevents(insulin:HR1.19[95%CI0.6022.40];log-ranktest,
P = 0.61; OHA: HR 0.84 [0.5721.24]; log-rank test, P =0 . 3 8 ) .C: In the diet-alone group, low-
dose aspirin signiﬁcantly reduced atherosclerotic events despite the lowest event rates (HR 0.21
[0.0520.64]; log-rank test, P = 0.0069).
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Okada and Associatespatients treated with insulin. Third, sev-
eral OHAs are reported to be beneﬁcial
for preventing cardiovascular events (e.g.,
metformin [24] and pioglitazone [25]),
b u tw ea n a l y z e dt h eO H Ag r o u pw i t h o u t
taking speciﬁc drug properties into ac-
count. Since most patients (81%) in the
OHAgrouptooksulfonylureaatbaseline,
we could not assess the single-agent ef-
fectsofthecardioprotectiveOHAs.Finally,
the number of hemorrhagic events was
v e r yl o wi nb o t ht h ea s p i r i na n dn o -
aspiringroups;however,thesamplesizes
were too small to estimate aspirin’ss i d e
effects in the JPAD trial. Therefore, we
could not make ﬁrm conclusions about
the safety of low-dose aspirin based on
our results.
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